Chronic lymphocytic leukaemia (CLL) is a type of cancer in which too many white blood cells are produced. These cells develop abnormally and are unable to function and fight infection. They also prevent the production of other healthy blood cells. As the disease is chronic, it develops very slowly over time. CLL is one of the most common type of leukaemia in adults, usually occurring in the elderly population. High risk CLL is cancer that does not get better with treatment. General symptoms of CLL include: fatigue, frequent infections, swollen lymph nodes (commonly in the neck, armpits and groin), anaemia, easy bruising/bleeding, enlarged spleen (causing tender lump in upper left abdomen), night sweats and weight loss.
The combination of ublituximab (intravenous infusions) and ibrutinib (oral capsules) is being developed as a new treatment option for patients with high risk CLL. Both drugs act in different unique ways to improve the body’s natural defence to fight the cancer cells and their combined effect may significantly reduce symptoms of the disease and increase survival. If licensed, the combination of ublituximab and ibrutinib will offer an additional treatment option for patients with high risk CLL who have received other previous treatment. This combination has the potential to improve effectiveness by offering a quicker time to response and a greater depth of response compared with ibrutinib alone.
Triptorelin is being developed as an injection under the skin (subcutaneous) for the treatment of locally advanced or metastatic prostate cancer. It is already marketed for this condition but is given by injection deep into the muscles (intramuscular). Triptorelin is an artificial analogue of natural gonadotropin‐releasing hormone that acts to slowly reduce the level of testosterone in the body. The first administration of triptorelin stimulates an increase in testosterone levels but prolonged administration leads to a fall in plasma testosterone or oestradiol to castrate levels which is maintained for as long as the product is administered. Triptorelin as a subcutaneous injection formulation has the potential advantage of improved safety and local tolerability when compared to intramuscular injection formulation.